Psoriatic arthritis and GLP-1RA therapy

[Fred]

Glucagon-like peptide-1 receptor (GLP-1RA) agonist therapy is associated with improvement in psoriatic arthritis (PsA) related and metabolic outcomes.

Quote:

---

Objectives:
Obesity is highly prevalent in psoriatic arthritis (PsA) and associates with worse disease outcomes. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly being used for weight loss and diabetes, but their impact on PsA outcomes remains unclear. We aimed to characterize patients with PsA initiating GLP-1RAs and assess longitudinal changes in weight, PsA activity and cardiometabolic parameters.

Methods:
We conducted a retrospective analysis of patients with PsA who initiated GLP-1RAs. PsA disease activity data and cardiometabolic parameters from clinical visits within 1 year before and after GLP-1RA initiation along with demographics and comorbidities were collected.

Results:
48 patients with a median BMI 34.9 were included. Significant weight loss was observed post-treatment (-6.43 kg (95% CI -9.5, -2.0), p< 0.0001), with 60% losing ≥5 % of their baseline bodyweight. CRP levels (-1.1 mg/L, p=0.002), pain scores (-1.0, p=0.01), and triglyceride levels (-0.35 mmol/L, p=0.02) decreased significantly. Each 1% reduction in body weight was associated with significant improvements in DAPSA [β=-0.49 (95% CI: -0.94, -0.03)], tender joint count [β=-0.18 (95% CI: -0.32, -0.05)], EQ-5D [β=0.0016 (95% CI: 0.008, 0.023)], LDL [β=-0.05 (95% CI: -0.10, -0.003)], and systolic blood pressure [β=-0.67 (95% CI: -1.18, -0.15)].

Conclusion:
In this real-world study, GLP-1RA therapy in PsA was associated with clinically meaningful weight loss and improvements in systemic inflammation, pain, and cardiometabolic markers. Improvements in psoriatic outcomes were proportional to the degree of weight loss. These findings warrant further investigation in prospective controlled studies to evaluate the role of GLP-1RAs in PsA management and comorbidities.

Source: onlinelibrary.wiley.com

*Funding: Early view funding unknown

[Turnedlight]

My first thought was - perhaps the docs will think ‘I can help mrs tl lose weight and improve arthritis - what a great idea and probably better one than immune suppressing which just holds down the symptoms’.

But then I remembered - this is the NHS.

[Turnedlight]

My first thought was - perhaps the docs will think ‘I can help mrs tl lose weight and improve arthritis - what a great idea and probably better one than immune suppressing which just holds down the symptoms’.

But then I remembered - this is the NHS.

[Fred]

My first thought was - perhaps the docs will think ‘I can help mrs tl lose weight and improve arthritis - what a great idea and probably better one than immune suppressing which just holds down the symptoms’.

But then I remembered - this is the NHS.

[Caroline]

GLP-1 is that in normal language Ozempic?

Seems that losing weight has effect.
But as easily it can be that the change in microbiome does the job.
Losing weight of course reduces the pressure on your limbs.

[mataribot]

We would be interested in the long term results these drugs are known to mess with your bones. I disagree with Caroline - they drugs mess with your ability to digest food. In some cases, your food spoils before it’s digested causing lots of problems.

[Caroline]

We would be interested in the long term results these drugs are known to mess with your bones. I disagree with Caroline - they drugs mess with your ability to digest food. In some cases, your food spoils before it’s digested causing lots of problems.

Thanks for your reaction Mata. Certainly good to know the long term results and I did not know the side effects of this type of medication.
Will take an extra look at them.
For myself no need to use them.

[mataribot]

My wife has been on and off them they all do the same thing. You’re not hungry if you always have food in your stomach, but that comes with consequences. I think diet and exercise is the best approach if you can physically able to do it.